ATHA צמיחה צפויה ברווח למניה לשנה הבאה athira.com

Athira Pharma, Inc. (ATHA) maintains a high reputation for developing small molecules to combat Alzheimer's disease. The forward earnings per share growth forecast in the GURU.Markets terminal displays a chart of the metric, where the latest value is recorded as 21.60. While geopolitical strife and sanctions hinder global dementia research, demand for neuro-products provides the company with resilience against market cycles.
פילוחים אנליטיים ודוחות נתונים של חברת Athira Pharma Inc (ATHA)

The development of Alzheimer's disease treatments within US healthcare standards provides Athira Pharma, Inc. (ATHA) with a stable environment for clinical trials. Current expectations for EPS n+1 growth aggregate analyst consensus forecasts, measuring future business efficiency through earnings per share dynamics. This indicator allows the market to filter out noise, determining the fundamental cost of capital based on expected returns.